Fate therapeutics announces pricing of $100 million underwritten offering and concurrent private placement

San diego, march 19, 2024 (globe newswire) -- fate therapeutics, inc. (the “company” or “fate therapeutics”) (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (ipsc)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. the offering includes participation from new and existing institutional investors, including adage capital partners lp., boxer capital, deep track capital, orbimed, suvretta capital and a life-sciences focused investor.
FATE Ratings Summary
FATE Quant Ranking